PDS Biotechnology Corp Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
PDS Biotechnology Corp (PDSB) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $8.70 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-03-30
- PDS Biotechnology Corp valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $8.70M, a 8.75% increase from fiscal 2024.
- PDS Biotechnology Corp valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $8.00M, a 43.66% decline from fiscal 2023.
- PDS Biotechnology Corp valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $14.20M, a 19.33% increase from fiscal 2022.
- PDS Biotechnology Corp valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $11.90M, a 2875.00% increase from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|
| 2025-12-31 | $8.70M 10-K · filed 2026-03-30 |
| 2024-12-31 | $8.00M 10-K · filed 2025-03-27 |
| 2023-12-31 | $14.20M 10-K · filed 2024-03-28 |
| 2022-12-31 | $11.90M 10-K · filed 2023-03-28 |
| 2021-12-31 | $400.00K 10-K · filed 2022-03-31 |
| 2020-12-31 | $4.00M 10-K · filed 2021-03-18 |
| 2019-12-31 | $20.80M 10-K · filed 2020-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |